Genmab — Marts 2018
-
FDA stopper atter forsøg med kræftmiddel efter dødsfald
De amerikanske sundhedsmyndigheder har stoppet et klinisk studie med et kræftmiddel efter et dødsfald. Det er anden gang, at FDA ser sig nødsaget til at gøre det overfor selvsamme selskab. Aktien falder markant ovenpå nyheden.
(medwatch.dk)
-
Dara + Tecentriq H2, Estimated Primary Completion Date: July 25, 2018. https://clinicaltrials.gov/ct2/show/NCT03023423
-
Dette er da rabatter der er til at forstå. Godt og vel prisen på Genmab.
https://medwatch.dk/Medicinal___Biotek/article10402951.ece -
Yes, it is an industry wide trend, JNJ saying "However, Duato said the company wasn't concerned about this, because J&J's strategy is to grow through volume rather than price increases" https://www.foxbusiness.com/markets/forget-remicade-heres-how-johnson-johnson-plans-to-grow
-
Forget Remicade -- Here's How Johnson & Johnson Plans to Grow
Three ways the healthcare giant intends to keep its pharma business growing despite declining sales for its top-selling drug.
Yahoo Finance (finance.yahoo.com)
-
As for Darzalex, Duato stated that J&J has a "very ambitious development program" for the drug. He said that Darzalex already claims a market share of around 20% as a second-line treatment for multiple myeloma. The "next wave of growth" for the drug will be in the first-line setting, according to Duato. He said J&J considers the drug as a backbone therapy in multiple myeloma.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind